Galectin Therapeutics Secures $10 Million Credit Line, Advances Belapectin Program With FDA Feedback.

Galectin Therapeutics has received written feedback from the FDA on its Belapectin program for MASH cirrhosis and portal hypertension. The FDA has aligned with Galectin on the patient population for a registration trial and plans to extend a follow-up Type C meeting to finalize trial design elements and present new biomarker data. Galectin has also secured a $10 million credit line to fund expenditures through at least March 2027.